Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Valeant Pharmaceuticals initiate Phase II retigabine study

Valeant Pharmaceuticals initiate Phase II retigabine study

29th November 2007

Valeant Pharmaceuticals initiates Phase II retigabine study

Valeant Pharmaceuticals has announced that it has enrolled the first patient in its Phase II clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN).

PHN is a painful and common complication of shingles where patients experience a painful blistering rash that lasts for several weeks.

The study is intended to enrol a total of 180 patients with 120 patients earmarked for treatment of retigabine and 60 intended to receive a placebo treatment for ten weeks.

Conducted over 40 trial locations, study patients will be titrated to their individually determined maximum tolerated dose within the range of 300mg to 900mg per day.

The average pain intensity over the last seven days of maintenance therapy will be used as the primary outcome assessment with pain intensity measured using a scale of zero to ten.

Timothy Tyson, president and chief executive officer of Valeant, expressed his excitement over the investigation into the efficacy of retigabine.

“Retigabine shows promise as an effective analgesic in animal pain models. We are optimistic that retigabine might offer a much-needed, new option for physicians treating patients with debilitating and painful conditions such as PHN.”

Last month, Valeant Pharmaceuticals announced that it was to collaborate with Ascend Therapeutics to aid in the promotion of its Migranal (dihydroergotamine mesylate, USP) Nasal Spray.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.